The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Interim safety and efficacy results from AURELIO-03: A phase 1 dose escalation study of the IL-2/IL-15 receptor βγ superagonist SOT101 as a single agent and in combination with pembrolizumab in patients with advanced solid tumors.
 
Elena Garralda
Consulting or Advisory Role - Alkermes; Anaveon; Boehringer Ingelheim; Bristol-Myers Squibb; Ellipses Pharma; F-Star Therapeutics; Hengrui Therapeutics; Janssen; MAB Discovery; NeoMed; Roche; Seagen; Thermo Fisher Scientific
Speakers' Bureau - Lilly; MSD; Novartis; Roche; Thermo Fisher Scientific
Research Funding - AstraZeneca/MedImmune (Inst); BeiGene (Inst); Novartis (Inst); Roche (Inst); Taiho Oncology (Inst); Thermo Fisher Scientific (Inst)
Other Relationship - Affimed Therapeutics (Inst); Amgen (Inst); Anaveon (Inst); AstraZeneca (Inst); BioNTech (Inst); Catalym (Inst); CytomX Therapeutics (Inst); F-Star Beta Limited (Inst); F. Hoffmann LaRoche (Inst); Genentech (Inst); Genmab (Inst); Hutchison MediPharma (Inst); Imcheck Therapeutics (Inst); Immunocore (Inst); Janssen-Cilag SA (Inst); MedImmune (Inst); Merck KGaA (Inst); Novartis (Inst); Peptomyc (Inst); Ribon Therapeutics (Inst); Roche (Inst); Seagen (Inst); Symphogen (Inst); Taiho Pharmaceutical (Inst)
 
Aung Naing
Consulting or Advisory Role - CSL Behring (I); CytomX Therapeutics; Deka Biosciences; Genome & Company; Horizon Pharma (I); Kymab; Novartis; OncoSec; Pharming NV (I); STCube Pharmaceuticals Inc.; Takeda (I)
Research Funding - Amplimmune; Arcus Biosciences; ARMO BioSciences; Atterocor; Baxalta (I); BioNTech SE; Bristol-Myers Squibb; Calithera Biosciences; Chao Physician-Scientist Awards (I); CytomX Therapeutics; EMD Serono; Healios; Immune Deficiency Foundation (I); ImmuneOncia; Incyte; Jeffrey Modell Foundation (I); Karyopharm Therapeutics; Kymab; Lilly; MedImmune; Merck; Monopteros Therapeutics; NCI; NeoImmuneTech; Neon Therapeutics; Novartis; Pfizer; PsiOxus Therapeutics; Regeneron; Seven and Eight Biopharmaceuticals; Sotio; Surface Oncology; TopAlliance BioSciences Inc
Travel, Accommodations, Expenses - ARMO BioSciences
 
Vladimir Galvao
No Relationships to Disclose
 
Patricia LoRusso
Honoraria - Five Prime Therapeutics
Consulting or Advisory Role - Abbvie; ABL Bio; Agenus; Agios; Astellas Pharma; AstraZeneca; BAKX Therapeutics; Bayer; Black Diamond Therapeutics; Compass Therapeutics; Cybrexa Therapeutics; CytomX Therapeutics; EMD Serono; Five Prime Therapeutics; Genentech; Genmab; GlaxoSmithKline; Halozyme; I-Mab; ImCheck therapeutics; ImmunoMet; IQvia; Kineta; Kyowa Kirin International; Macrogenics; Mekanistic Therapeutics; Molecular Templates; Molecular Templates; Pfizer; QED Therapeutics; Relay Therapeutics; Roche/Genentech; Salarius Pharmaceuticals; Seagen; Shattuck Labs; Silverback Therapeutics; SK Life Sciences; Sotio; ST Cube; Stemline Therapeutics; Takeda; Trial to Reduce IDDM in the Genetically at Risk (TRIGR); TYME; Zentalis
Research Funding - Genentech (Inst)
Travel, Accommodations, Expenses - Genentech
 
Peter Grell
Consulting or Advisory Role - Roche; SERVIER
Travel, Accommodations, Expenses - SERVIER
 
Philippe Alexandre Cassier
Honoraria - Amgen; ITeos Therapeutics; Janssen
Consulting or Advisory Role - OSE Immunotherapeutics
Research Funding - Abbvie (Inst); AstraZeneca (Inst); Bayer (Inst); Blueprint Medicines (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); GlaxoSmithKline (Inst); Innate Pharma (Inst); Janssen (Inst); Lilly (Inst); Loxo (Inst); Merck Serono (Inst); Merck Sharp & Dohme (Inst); Novartis (Inst); Plexxikon (Inst); Roche/Genentech (Inst); Taiho Pharmaceutical (Inst); Toray Industries (Inst); Transgene (Inst)
Travel, Accommodations, Expenses - Amgen; AstraZeneca/MedImmune; Merck Serono; Merck Sharp & Dohme; Netris Pharma; Roche
 
Carlos A. Gomez-Roca
Honoraria - Bristol-Myers Squibb; Eisai; Foundation Medicine; Genentech/Roche; Pierre Fabre
Consulting or Advisory Role - Bristol-Myers Squibb; Ellipses Pharma; Macomics
Research Funding - Amgen (Inst); Bristol-Myers Squibb (Inst); Roche/Genentech
Travel, Accommodations, Expenses - MSD Oncology; Pierre Fabre; Roche/Genentech
 
Iphigenie Korakis
No Relationships to Disclose
 
David Bechard
Employment - Cytune Pharma
Leadership - Cytune Pharma
Patents, Royalties, Other Intellectual Property - Cytune Pharma
(OPTIONAL) Uncompensated Relationships - Sotio
 
Lenka Palova Jelinkova
Employment - Sotio
 
Irena Adkins
Employment - Sotio
Research Funding - Sotio
Patents, Royalties, Other Intellectual Property - SctBio; Sotio
Travel, Accommodations, Expenses - Sotio
 
Sascha Tillmanns
Employment - Sotio
 
Joachim Kiemle-Kallee
Employment - Sotio
 
Aurelien Marabelle
Stock and Other Ownership Interests - Centessa Pharmaceuticals; Centessa Pharmaceuticals (Inst); Deka Biosciences; HiFiBiO Therapeutics; HotSpot Therapeutics; PEGASCY (Inst); Shattuck Labs
Consulting or Advisory Role - AstraZeneca; BiolineRx; Centessa Pharmaceuticals; Clover Biopharmaceuticals; Deka Biosciences; Depth Charge Therapeutics; Eisai; Gritstone Bio; HiFiBiO Therapeutics; Hotspot Therapeutics; ImCheck therapeutics; Innate Pharma; Johnson & Johnson/Janssen; Lytix Biopharma; Medicxi; MedinCell; MSD; OSE Immunotherapeutics; Pierre Fabre; Redx Pharma; Roche; SERVIER; Shattuck Labs; Sotio; Third Rock Ventures
Research Funding - Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); MSD (Inst); Transgene (Inst)
Patents, Royalties, Other Intellectual Property - monoclonal antibodies against CD81 (Stanford University)
Travel, Accommodations, Expenses - Sotio
 
Stephane Champiat
Honoraria - Amgen; AstraZeneca/Merck; Bristol-Myers Squibb; Eisai; Janssen; MSD; Novartis; Roche
Consulting or Advisory Role - Alderaan Biotechnology; Amgen; AstraZeneca/Merck; Avacta Life Sciences; Ellipses Pharma; Oncovita; Seagen; UltraHuman
Research Funding - Abbvie (Inst); Amgen (Inst); Cytovation (Inst); Eisai (Inst); Imcheck Therapeutics (Inst); Molecular Partners (Inst); MSD (Inst); ose pharma (Inst); Pierre Fabre (Inst); Sanofi Aventis GmbH (Inst); Transgene (Inst)
Travel, Accommodations, Expenses - AstraZeneca/Merck; MSD; ose pharma; Roche; Sotio